Antidiabetic Action of Alfalfa (Medicago sativa) Leaves Powder on Type II Diabetic Patients

Authors

  • Burhan A. Salih Department of Medical Laboratory Technology, Hawler Health Technical College, Erbil Polytechnic University, Erbil, Kurdistan Region - F.R. Iraq
  • Kokaz O. Azeez Department of Medical Laboratory Technology, Hawler Health Technical College, Erbil Polytechnic University, Erbil, Kurdistan Region - F.R. Iraq

DOI:

https://doi.org/10.25156/ptj.v9n1y2019.pp23-25

Keywords:

Alfalfa, Insulin, Type II diabetes

Abstract

Type II diabetes is a common metabolic disorder that is specified by hyperglycemia resulting from defects in insulin action. Alfalfa (Medicago sativa) is a medicinal plant (leaves, flower, and seeds) used traditionally as antidiabetic. This study is designed to investigate the short-term antidiabetic action of alfalfa leaves powder in patients with Type II diabetes mellitus. 12 volunteers suffering from type II diabetes were undertaken besides 12 healthy individuals. The subjects were divided into four groups including healthy control, diabetic control, which received an only meal, and the third and fourth groups were healthy and diabetic subjects which received alfalfa leaves powder within the meal. A standard test meal was supplemented with 8 g of alfalfa. The results showed that alfalfa leaves significantly (P = 0.03) reduces blood sugar 2 h after meal from 344.4 mg/dl to 300.75 mg/dl in the diabetic subject, in addition to the elevation of serum insulin levels (P = 0.02) at 30 min and elevation further creased (P = 0.06) at 120 min. This finding suggested that alfalfa leaves could be applied as a therapy against Type II diabetes.

Downloads

Download data is not yet available.

References

Amraie, E., Farsani, M. K., Sadeghi, L., Khan, T. N., Babadi, V. Y., Adavi, Z. 2015. The effects of aqueous extract of alfalfa on blood glucose and lipids in alloxan-induced diabetic rats. Intervent.
Med. Appl. Sci. 7(3): 124-128.

Asgary, S., J. Moshtaghian, M. Hosseini and H. Siadat. 2008. Effects of alfalfa on lipoproteins and fatty streak formation in hypercholesterolemic rabbits. Pak. J. Pharm. Sci. 21(4):
460-464.

Aydin, Y. and E. Önder. 2016. Herbal self-medication use in Type 2 diabetes mellitus. Turk. J. Med. Sci. 46: 1275-1276.

Gray, A. M. and P. R. Flatt. 1997. The traditional plant treatment, Sambucus nigra (elder), exhibits insulin-like and insulinreleasing actions in vitro. J. Nutr. 78: 325-334.

Gray, A. M. and P. R. Flatt. 1998. Antihyperglycemic actions of Eucalyptus globulus (Eucalyptus) areassociated with pancreatic and extra-pancreatic effects in mice. Am. Soc. Nutr. Serv.
128: 2319-2323.

Gregersen, S., P. B. Jeppesen, J. J. Hols and K. Hermansen. 2004. Ant hyperglycemic effects of stevioside in Type 2 diabetic subjects. Metabolism. 53: 73-76.
Mölgaard, J., H. von Scheck and A. G. Olsson. 1987. Alfalfa seeds lower low density lipoprotein cholesterol and apolipoprotein B concentrations in patients with Type II hyperlipoproteinemia.
Atherosclerosis. 65(1-2): 173-179.

Nathan, D. M. 2014. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years. Overv. Group J. Diabetes Care. 37(1): 44-49.

Sharma, H. and S. Kumar. 2016. Management of metabolic syndrome by some herbs ethnic to Western Himalayan region of Himachal Pradesh. J. Pharmacogn. Phytochem. 5(3): 192-195.

Swanston-Flatt, S. K., C. Day, C. J. Bailey and P. R. Flatt. (1990) Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Diabetologia. 33(8): 462-464.
Volume 9 Number 1 (2019)

Downloads

Published

2019-06-13

How to Cite

Salih, B. A. ., & Azeez, . K. O. . (2019). Antidiabetic Action of Alfalfa (Medicago sativa) Leaves Powder on Type II Diabetic Patients. Polytechnic Journal, 9(1), 23-25. https://doi.org/10.25156/ptj.v9n1y2019.pp23-25

Issue

Vol. 9 No. 1 (2019)

Section

Research Articles

License

Copyright (c) 2019 Burhan A. Salih, Kokaz O. Azeez

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors who publish with this journal agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-ND 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).